Transdermal Dextroamphetamine (Xelstrym) for ADHD
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1669d ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Methylphenidate.
Abstract (Originalsprache)
The FDA has approved a dextroamphetamine transdermal patch (Xelstrym – Noven) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Xelstrym is the first transdermal amphetamine product to be approved in the US. A methylphenidate transdermal patch (Daytrana, and generics) has been available for years for treatment of ADHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Transdermal Dextroamphetamine (Xelstrym) for ADHD. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1669d
Vancouver
Transdermal Dextroamphetamine (Xelstrym) for ADHD. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1669d
BibTeX
@article{euvimed2023,
title = {Transdermal Dextroamphetamine (Xelstrym) for ADHD},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1669d}
}
EUVIMED